In Europe, in the first two weeks of January, Mergermarket aggregated seven funds at various stages of raising capital. This included Foresight Group's EUR 430m first close of its energy infrastructure fund, which has a target of EUR 500m and hard-cap of EUR 750m.
There were also two funds which will look to invest in the pharma, medical & biotech space, namely Life Sciences Partners’ LSP Dementia Fund, which has a target of EUR 150m, and BioGeneration Venture’s fourth fund, which has raised EUR 140m. The latter will invest up to EUR 20m per deal in 12-15 companies. The pharma, medical & biotech space has become increasingly active for sponsors in recent years. The sector saw 152 buyouts worth a combined EUR 23.7bn in Europe in 2020, its highest annual value and volume on Mergermarket record.
Funds In The MarketTo access please sign in.